J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297
J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have chronic atopic dermatitis
Participants must have had unsatisfactory results with existing medications applied to the skin
Participants must NOT
Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)
Participants must not have certain types of infection
Participants must not have other skin conditions or diseases that would interfere with the study
Participants must not have a history of certain types of cancers
Participants must not be pregnant or breastfeeding
Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline
Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
240
Trial Dates
November 2020 - January 2022
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have chronic atopic dermatitis
Participants must have had unsatisfactory results with existing medications applied to the skin
Participants must NOT
Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)
Participants must not have certain types of infection
Participants must not have other skin conditions or diseases that would interfere with the study
Participants must not have a history of certain types of cancers
Participants must not be pregnant or breastfeeding
Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline
Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
240
Trial Dates
November 2020 - January 2022
Trial Phase
3
Trial Locations
Hide locations not currently recruiting